The Latest Breaking News from Kymera

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD).  In…

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ:KYMR) with a Neutral rating and a $44 price target.  Analyst Eric Joseph says that the Company is "relatively insulated from downside pressure versus the benchmark from a healthy balance sheet."  At the end of 2021, Kymera held approximately $567.6 million in cash, cash equivalents, and investments.…